Titlebook: Cancer; Robert H. Bradbury Book 2007 Springer-Verlag Berlin Heidelberg 2007 Cancer.Chemotherapy.Tumour.angiogenesis.biology.chemistry.medi

人造

Survival Signaling,ole in controlling cell growth, proliferationand survival. Whatever the mechanism, the prevalence of PI3K/PKB signaling abnormalities in human cancercells has suggested the potential use of PI3K/PKB pathway modulators as novel targeted therapeutic agents.Although often non-selective for the intended

连词

Progress in the Development of Agents to Control the Cell Cycle,rts have focused on inhibitors of the cyclin-dependentkinases, the Aurora kinases, and Polo-like kinases. Agents for each kinase are now advancing in humanclinical trials. In this review we will summarize the work in this area with special emphasis onthe structural biology and structure–activity rel

Annotate

HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinicical background of HDACs and their link to cancer andcancer treatment. The body of the work consists of a categorized and chronological medicinal chemistryoverview. This part describes key medicinal chemistry contributions ranging from the very early HDAC inhibitorsto compounds currently in the clin

使服水土

Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer of the molecular mechanisms underlyingthe angiogenesis process have led to the discovery of a variety of pharmaceutical agents withantiangiogenic activity. The potential application of these angiogenesis inhibitors is currentlyunder intense clinical investigation. Decades of investigation suggest t

发出眩目光芒

META

Bcr-Abl Kinase Inhibitors,-phenyl aminopyrimidine Bcr-Abl inhibitor developedby Novartis and marketed under the tradename of Gleevec (Glivec), is highly effective in treating CML patientswith early stage disease. However, patients with advanced disease often become resistant to imatinib. Thepredominant form of this resistanc

DUCE

Coterminous

Neuroprotection for Photoreceptorsased potency and efficacy, improved tissueselectivity, and without any agonistic activity will be described. New pre-clinical and clinical data ondevelopment candidates will be reported. Advanced breast and prostate cancer is effectively managed byestrogen and androgen ablation, respectively. Howeve

Eosinophils

degradation

https://doi.org/10.1007/978-981-99-7269-2logy of the VEGF family of ligands and receptors and of VEGFR-2 in particular.The attempts to develop effective VEGFR-2 antagonists, including small molecules, antibodies and others,for therapeutic purposes are discussed comprehensively with special emphasis on tumor angiogenesis.